Monoclonal Antibodies - Is There Resistance?

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

There are some people who are quite concerned that if you start rolling out individual monoclonal annabody therapie s on a wide scale tat you're going to encourage the development of resistance. So that is a concern. There was an interesting development in that case, i guess, with one of the antabodies that had clinical trial results announced last week. And that particular annaboty targets a bit of a protein that tends to not mutate, tends to stay very stable.

In the early days of the pandemic, researchers raced to identify the most potent antibodies produced by the immune system in response to SAR-COV-2 infection and produce them in bulk. The resulting ‘monoclonal antibodies’ have since been tested in a variety of settings as treatments for COVID-19.

But despite promising clinical trial results and several therapies having already been approved, antibody therapies have not yet played a large role in the fight against COVID-19. In this episode of Coronapod, we ask why.

News: COVID antibody treatments show promise for preventing severe disease

News: Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Hosted on Acast. See acast.com/privacy for more information.